Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046703 | 0.93 | CHRNB2 (0.42) | CHRNB2CHRNA7CHRNA4ALDH1A1HPGD | |
| SCHEMBL4049254 | 0.93 | CHRNB2 (0.40) | CHRNB2CHRNA7CHRNA4ALDH1A1HPGD | |
| SCHEMBL4043537 | 0.91 | PIK3CG (0.37) | CHRNB2CHRNA7CHRNA4ALDH1A1HPGD | |
| SCHEMBL4046322 | 0.90 | CHRNB2 (0.38) | CHRNB2CHRNA7CHRNA4ALDH1A1HPGD | |
| SCHEMBL4043842 | 0.89 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4ALDH1A1HPGD | |
| SCHEMBL4045043 | 0.89 | HPGD (0.38) | ALDH1A1HPGD | |
| SCHEMBL4043880 | 0.88 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA4ALDH1A1HPGD | |
| SCHEMBL4048699 | 0.85 | CTSK (0.40) | — | |
| SCHEMBL4040754 | 0.85 | CTSK (0.40) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4046863 | 0.84 | SMYD3 (0.35) | CHRNB2CHRNA7CHRNA4SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111050765-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-107098846-B | N-acyl sulfonamide FBPase inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-10-09 | — | — | CN | disclosed |
| CN-111050765-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-7253281-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | BENTLEY JONATHAN M | 2007-05-10 | — | — | US | disclosed |
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | BENTLEY JONATHAN M | 2005-10-27 | — | — | US | disclosed |
| EP-1325008-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | EP | disclosed |
| US-6933387-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | GPR119, INSR, GIPR | CHRNB2 2890/4885CHRNA7 1044/4885CHRNA4 998/4885 |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | GPR119, INSR, IRS1 | CHRNB2 2758/4885CHRNA7 1739/4885CHRNA4 1769/4885 |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | GPR119, INSR, GIPR | CHRNB2 2890/4885CHRNA7 1044/4885CHRNA4 998/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | CHRNB2 2754/4885CHRNA7 2457/4885CHRNA4 2705/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | CHRNB2 1498/4885CHRNA7 359/4885CHRNA4 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.